Day One: Tuesday September 18, 2018

REGISTRATION & BREAKFAST

8:00

8:00

Introduction and Summary

8:15

Novel Antibody Constructs

8:30

8:30

SIFbody: A best-in-class tumor cell killing platform for hematologic malignancies

 

 

Amit Choudhury

Principal Scientist

 

Momenta

9:00

9:00

 

CD38 A2 human monoclonal antibody:  a Franchise in a molecule

Robert Knight
Senior Vice-President, Head of Clinical Research

 

Sorrento

9:30

9:30

Preclinical characterization of an Anti-IL1RAP Antibody-Drug Conjugate for Dual Targeting of Leukemic Stem Cells and Blast Cells of Acute Myeloid Leukemia

 

Jagath Reddy Juntula

Vice President, R&D

Cellerant

10:00

MANUFACTUING OF ADCs: CHALLENGES IN SCALING UP and PROCESS FROM CLINICAL TO COMMERCIAL

Giorgio Salciarini

Technical Business Development Manager

 

BSP Pharmaceuticals

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

10:30

Immunotherapy & CAR-TCR

11:30

FLX475, a potent and selective CCR4 Antagonist for treatment of EBV-Associated Tumors

Dirk Brockstedt

Senior Vice President, Biology

FLX Bio, Inc.

12:00

High Throughput Flow Cytometry Drug Sensitivity in Primary Blood Cancer Samples



Matthew De Silva

Founder, CEO

 

Notable Labs

LUNCH & NETWORKING

12:10

1:00

The Yin and Yang of Precision Medicine

Stefan Scherer

Senior Vice President, Clinical development and Deputy Chief Medical Officer

 

Cellectis

1:30

Multi-antigen targeting IMPACT CAR-T cells for hematologic malignancies: confronting antigen escape and tumor heterogeneity

 

Paul Rennert

President & CSO

 

Aleta Biotherapeutics

2:00

Translational Strategy to Support Clinical Development of Yescarta (Axicabtagene Ciloleucel), a First in Class CAR T Cell Product for Diffuse Large B Cell Lymphoma.

John Rossi

Director, Translational Sciences

Kite Pharma

2:30

TBC: P-BCMA-101: A BCMA-Specific CAR-T Stem Cell Memory Therapy for Multiple Myeloma

Devon J Shedlock

Vice President, Preclinical Development,

 

Poseida Therapeutics

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30

The Importance of Finding Cleaner Targets for Adoptive T-cell Therapies

 

Hans-Peter Gerber

Chief Scientific Officer and Senior Vice President

3T Biosciences

4:00

A pilot clinical study of low-dose anti-BCMA CAR-T in treating patients with r/r Multiple Myeloma

 

Jie Jia

VP, Strategic Alliances

 

CARsgen Therapeutics

4:30

T-cell Antigen Coupler (TAC) Technology: Co-opting the Natural T Cell Receptor to treat Liquid and Solid Tumors

 

Paul Lammers

CEO

 

Triumvira

DRINKS RECEPTION & NETWORKING

5:00

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2018 | All content produced by: Neo-Synth Ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF

A Novel Best-in-Class SIF-Body Platform to Enhance Tumor Cell Killing and Efficacy for Targeting Hematologic Malignancies

 

Amit Choudhury

Senior Scientist,

Momenta

CD38 A2 human monoclonal antibody:  a Franchise in a molecule

Robert Knight

SVP, Head of Clinical Research

 

Sorrento

Preclinical characterization of an Anti-IL1RAP Antibody-Drug Conjugate for Dual Targeting of Leukemic Stem Cells and Blast Cells of Acute Myeloid Leukemia

 

Jagath Reddy Juntula

Vice President, R&D
Cellerant

MANUFACTUING OF ADCs: CHALLENGES IN SCALING UP and PROCESS FROM CLINICAL TO COMMERCIAL

Giorgio Salciarini

Technical Business Development Manager,

BSP Pharmaceuticals

SPEED NETWORKING

FLX475, a potent and selective CCR4 Antagonist for treatment of EBV-Associated Tumors

 

Dirk Brockstedt

Senior Vice President, Biology

FLX Bio, Inc.

High Throughput Flow Cytometry Drug Sensitivity in Primary Blood Cancer Samples


Matthew De Silva
CEO

Notable Labs

The Yin and Yang of Precision Medicine

Stefan Scherer

Senior Vice President, Clinical development and Deputy Chief Medical Officer

 

Cellectis

Multi-antigen targeting IMPACT CAR-T cells for hematologic malignancies: confronting antigen escape and tumor heterogeneity

 

Paul Rennert

President & CSO

Aleta Biotherapeutics

Translational Strategy to Support Clinical Development of Yescarta (Axicabtagene Ciloleucel), a First in Class CAR T Cell Product for Diffuse Large B Cell Lymphoma.

John Rossi

Director, Translational Sciences, Kite Pharma

P-BCMA-101: A BCMA-Specific CAR-T Stem Cell Memory Therapy for Multiple Myeloma

Devon Shedlock

Senior Director, Immuno-Oncology,

 

Poseida Therapeutics

The Importance of Finding Cleaner Targets for Adoptive T-cell Therapies

 

Hans-Peter Gerber

Chief Scientific Officer and Senior Vice President

3T Biosciences

A pilot clinical study of low-dose anti-BCMA CAR-T in treating patients with r/r Multiple Myeloma

 

Jie Jia

VP, Strategic Alliances,

CARsgen Therapeutics

T-cell Antigen Coupler (TAC) Technology: Co-opting the Natural T Cell Receptor to treat Liquid and Solid Tumors

 

Paul Lammers

CEO

 

Triumvira